Molecular Profiling and Advanced Imaging Guide Personalized Treatment in Complex Secondary Meningioma After Childhood Medulloblastoma
核心洞察
A 49-year-old male survivor of childhood medulloblastoma (搜索) developed a large secondary meningioma (搜索) 44 years after initial treatment, highlighting late effects of craniospinal radiation.
Molecular testing reclassified the tumor from grade 1 to grade 2 atypical meningioma (搜索), demonstrating that histology alone does not tell the full story.
Dotatate PET/CT imaging identified residual disease outside the resection cavity, enabling personalized radiation dosing with a simultaneous integrated boost.
A 49-year-old male patient traveled from Peru to Cleveland Clinic Cancer Institute after a brain MRI revealed a six-centimeter meningioma (搜索) causing considerable pressure on his brain — a secondary cancer emerging 44 years after he was treated for grade 4 medulloblastoma (搜索) at age five.
The case, detailed by Cleveland Clinic radiation oncologist Erin Murphy, MD, and colleagues, illustrates how molecular profiling and advanced imaging are reshaping treatment decisions for meningiomas, particularly in patients with complex prior radiation exposure.
A Childhood Cancer Survivor's Second Diagnosis
At age five, the patient received the standard of care for grade 4 medulloblastoma (搜索): an intense regimen of surgery, craniospinal radiation, and chemotherapy. The treatment saved his life but placed him at risk for late effects, including neurocognitive dysfunction, decreased growth, hormone dysregulation, and secondary malignancies.
His parents never disclosed his cancer diagnosis to him, instead involving him in sports from an early age. "I believe that the fact that he got right back into being active with a healthy lifestyle and athletics impacted him dramatically," said Dr. Murphy. "Nowadays we have so many resources like speech therapy, physical therapy, occupational therapy and IEPs but at the time he was diagnosed there weren't as robust resources."
Four decades later, a puzzling neurological episode sent the patient to a local emergency room. Without imaging capabilities at that facility, he traveled to a medical center in Lima, where the brain MRI uncovered the large meningioma (搜索).
Surgical Intervention and Molecular Reclassification
Determined to find the best treatment, the patient traveled to Cleveland Clinic for consultation. Within days, neurosurgeon Matthew Grabowski, MD, performed a near-total resection in a 12-hour surgery, removing as much of the malignancy as possible while preserving nearby blood vessels. The patient was discharged earlier than expected.
Initial surgical pathology suggested a grade 1 meningioma (搜索). However, neuro-oncologist Alejandro Torres-Trejo, MD, arranged for molecular testing, which ultimately revealed markers consistent with a grade 2, or atypical, meningioma.
"There's still no consensus in the medical community of how to treat grade 2 meningiomas, but what we now know is that what cells look like under the microscope doesn't tell the whole story," Dr. Murphy explained. "This is a good example where molecular information can really help guide treatment."
Advanced Imaging Personalizes Radiation Strategy
The care team conducted a comprehensive workup that included a dotatate PET/CT scan, a highly specific imaging modality for meningiomas. The scan identified several areas of concern outside the resection cavity, and an MRI suggested potential progression — an unusual finding for what was initially thought to be a grade 1 tumor.
Based on both the molecular testing results and the dotatate PET findings, the team prescribed 6.5 weeks of comprehensive irradiation. The patient received a standard radiation dose to the entire resection cavity along with a simultaneous integrated boost targeting areas of residual tumor cells.
"Dotatate PET scans are very helpful for finding residual disease and checking for any other possible meningiomas," Dr. Murphy noted. "They can help guide us, giving us the option to deliver an additional boost of radiation to areas of residual disease."
Recovery and Ongoing Surveillance
Throughout his weeks of daily radiation, the patient remained highly motivated. His wife accompanied him to Cleveland, joining him on daily walks. Two weeks after completing radiation therapy, he was well enough to embark on a planned European vacation with his family.
"I always tell patients the better you get good nutrition, the more active you are and the better you stay hydrated, the better you'll be able to get through radiation therapy," said Dr. Murphy. "This patient was walking miles every day, eating well and enjoying life. He barely had any side effects. He was very positive and very driven. It made such a difference."
The patient continues to be monitored by his medical oncologist in Peru. His Cleveland Clinic care team arranged distance health visits to minimize international travel. He receives MRIs locally, which are sent to Cleveland Clinic for review, and maintains virtual follow-up appointments. Should any of the small remaining lesions grow, he would be a candidate for Gamma Knife radiosurgery, a less-invasive treatment option.